Development of Robust Orally Dispersible Powder Formulations
The poster on the development of a robust orally dispersible powder formulation for peadiatrics was presented by Graeme Macleod during the EUPFi in Malmö.
See the full Poster of SPI Pharma
The conclusion
ODP formulation requires careful consideration of the excipient properties relative to the API taste to ensure a robust patient friendly dose form is developed. Key issues that influence the formulation robustness are the API particle size, PSD of the carrier material and drug loading level. Choice of carriers such as Pharmasperse that are engineered specifically for ODP formulation, greatly improve the patient experience via enhanced organoleptics and ease of use, benefiting the formulator and patient alike.